CA19-9 decrease and overall survival (OS) in the NAPOLI-1 trial of liposomal irinotecan (nal-IRI) ± 5-fluorouracil and leucovorin (5-FU/LV) in metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy.
Chen, L Wang-Gillam, A Shan, Y Macarulla, T Blanc, J Chiu, C Schwartsmann, G Siveke, J Pipas J
Chen, L
Wang-Gillam, A
Shan, Y
Macarulla, T
Blanc, J
Chiu, C
Schwartsmann, G
Siveke, J
Pipas J
Citations
Altmetric:
Abstract
Description
Date
2017-06
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
CA19-9 decrease and overall survival (OS) in the NAPOLI-1 trial of liposomal irinotecan (nal-IRI) ± 5-fluorouracil and leucovorin (5-FU/LV) in metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy 2017, 28 (suppl_3) Ann Oncol